TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons

N Qin, MP Neeper, Y Liu, TL Hutchinson… - Journal of …, 2008 - Soc Neuroscience
N Qin, MP Neeper, Y Liu, TL Hutchinson, ML Lubin, CM Flores
Journal of Neuroscience, 2008Soc Neuroscience
Transient receptor potential V2 (TRPV2) has been proposed to be a high-threshold
thermosensor. However, further elucidation of the channel properties and physiological role
of TRPV2 have been hindered by the lack of selective pharmacological tools as well as by
the species-dependent differences in the activation of this channel. In the present study, we
have used cell-based calcium mobilization and electrophysiological assays to identify and
characterize several novel cannabinoid TRPV2 agonists. Among these, cannabidiol was …
Transient receptor potential V2 (TRPV2) has been proposed to be a high-threshold thermosensor. However, further elucidation of the channel properties and physiological role of TRPV2 have been hindered by the lack of selective pharmacological tools as well as by the species-dependent differences in the activation of this channel. In the present study, we have used cell-based calcium mobilization and electrophysiological assays to identify and characterize several novel cannabinoid TRPV2 agonists. Among these, cannabidiol was found to be the most robust and potent (EC50 = 3.7 μm), followed by Δ9-tetrahydrocannabinol (EC50 = 14 μm) and cannabinol (EC50 = 77.7 μm). We also demonstrated that cannabidiol evoked a concentration-dependent release of calcitonin gene-related peptide (CGRP) from cultured rat dorsal root ganglion neurons in a cannabinoid receptor- and TRPV1-independent manner. Moreover, the cannabidiol-evoked CGRP release depended on extracellular calcium and was blocked by the nonselective TRP channel blocker, ruthenium red. We further provide evidence through the use of small interfering RNA knockdown and repetitive stimulation studies, to show that cannabidiol-evoked CGRP release is mediated, at least in part, by TRPV2. Together, these data suggest not only that TRPV2 may comprise a mechanism whereby cannabidiol exerts its clinically beneficial effects in vivo, but also that TRPV2 may constitute a viable, new drug target.
Soc Neuroscience